CN102362867A - 使用ice抑制剂治疗癫痫发作 - Google Patents

使用ice抑制剂治疗癫痫发作 Download PDF

Info

Publication number
CN102362867A
CN102362867A CN2011101550931A CN201110155093A CN102362867A CN 102362867 A CN102362867 A CN 102362867A CN 2011101550931 A CN2011101550931 A CN 2011101550931A CN 201110155093 A CN201110155093 A CN 201110155093A CN 102362867 A CN102362867 A CN 102362867A
Authority
CN
China
Prior art keywords
chemical compound
epilepsy
ice
aspartic acid
cysteine protease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2011101550931A
Other languages
English (en)
Chinese (zh)
Inventor
A·韦扎尼
J·C·R·兰德尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertex Pharmaceuticals Inc
Original Assignee
Vertex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc
Publication of CN102362867A publication Critical patent/CN102362867A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CN2011101550931A 2004-05-15 2005-05-16 使用ice抑制剂治疗癫痫发作 Pending CN102362867A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57131404P 2004-05-15 2004-05-15
US60/571,314 2004-05-15

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CNA2005800228318A Division CN1980648A (zh) 2004-05-15 2005-05-16 使用ice抑制剂治疗癫痫发作

Publications (1)

Publication Number Publication Date
CN102362867A true CN102362867A (zh) 2012-02-29

Family

ID=34969808

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2011101550931A Pending CN102362867A (zh) 2004-05-15 2005-05-16 使用ice抑制剂治疗癫痫发作
CNA2005800228318A Pending CN1980648A (zh) 2004-05-15 2005-05-16 使用ice抑制剂治疗癫痫发作

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNA2005800228318A Pending CN1980648A (zh) 2004-05-15 2005-05-16 使用ice抑制剂治疗癫痫发作

Country Status (12)

Country Link
US (2) US20060128696A1 (enExample)
EP (1) EP1750689A1 (enExample)
JP (2) JP4848367B2 (enExample)
CN (2) CN102362867A (enExample)
AU (1) AU2005247409B2 (enExample)
CA (1) CA2566362C (enExample)
IL (1) IL179248A0 (enExample)
MX (1) MXPA06013256A (enExample)
NZ (1) NZ588448A (enExample)
PL (1) PL217743B1 (enExample)
WO (1) WO2005115362A1 (enExample)
ZA (1) ZA200610133B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105392775A (zh) * 2013-07-18 2016-03-09 辛泰格有限公司 旋光异构体：(+)-二苯甲基脲和(-)-二苯甲基脲以及(+)-1-[（3-氯苯基)-苯基-甲基]脲和(-)-1-[（3-氯苯基)-苯基-甲基]脲，它们的药物制剂及其制备方法

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7531570B2 (en) * 2004-05-27 2009-05-12 Vertex Pharmaceuticals Incorporated Treatment of diseases using ICE inhibitors
RU2446800C2 (ru) * 2006-05-31 2012-04-10 Вертекс Фармасьютикалз Инкорпорейтед Препаративные формы с контролируемым высвобождением
US20120301463A1 (en) 2009-09-30 2012-11-29 President And Fellows Of Harvard College Methods for Modulation of Autophagy Through the Modulation of Autophagy-Enhancing Gene Products
US9956260B1 (en) 2011-07-22 2018-05-01 The J. David Gladstone Institutes Treatment of HIV-1 infection and AIDS
WO2017153800A1 (en) * 2016-03-10 2017-09-14 Orphelia Pharma Solid dosage forms of vigabatrin
MX2022013549A (es) 2020-05-01 2023-01-16 Medstar Health Inc Metodos para tratar la covid-19.
WO2024097731A2 (en) * 2022-11-02 2024-05-10 Medstar Health, Inc. Methods for treating covid-19

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1229412A (zh) * 1995-12-20 1999-09-22 沃泰克斯药物股份有限公司 白细胞介素－1β转化酶抑制剂
WO2001090070A2 (en) * 2000-05-23 2001-11-29 Vertex Pharmaceuticals Incorporated Caspase inhibitors and uses thereof
US20020013278A1 (en) * 2000-05-19 2002-01-31 Wannamaker Marion W. Prodrug of an ice inhibitor
US6531474B1 (en) * 1998-03-19 2003-03-11 Vertex Pharmaceuticals Incorporated Inhibitors of caspases

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985863A (en) * 1996-09-12 1999-11-16 Vertex Pharmaceuticals, Inc. Compositions and methods for decreasing IGIF and IFN-γ production by administering an ICE inhibitor
US5874424A (en) * 1995-12-20 1999-02-23 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β converting enzyme
US6995141B1 (en) * 1990-04-04 2006-02-07 Vertex Pharmaceuticals Incorporated Interleukin 1β protease and interleukin 1β protease inhibitors
US5416013A (en) * 1990-04-04 1995-05-16 Sterling Winthrop Inc. Interleukin 1β protease and interleukin 1β protease inhibitors
EP0600880B1 (en) 1991-08-30 2004-01-07 Vertex Pharmaceuticals Incorporated Interleukin 1- beta protease and interleukin 1-beta protease inhibitors
US5985838A (en) * 1993-04-29 1999-11-16 Vertex Pharmaceuticals, Inc. Peptide analogs as irreversible interleukin-1β protease inhibitors
US5462939A (en) * 1993-05-07 1995-10-31 Sterling Winthrop Inc. Peptidic ketones as interleukin-1β-converting enzyme inhibitors
JPH0789951A (ja) * 1993-06-03 1995-04-04 Sterling Winthrop Inc インターロイキン−１β転換酵素阻害剤
US5843905A (en) * 1993-06-04 1998-12-01 Vertex Pharmaceuticals, Incorporated Peptidic phosphinyloxymethyl ketones as interleukin-1β-converting enzyme inhibitors
EP0628550B1 (en) * 1993-06-08 1998-02-25 Sanofi Pyridazines as interleukin-1beta converting enzyme inhibitors
EP0752987B1 (en) * 1994-03-31 2003-11-12 Vertex Pharmaceuticals Incorporated Pyrimidinyl derivatives as interleukin inhibitors
US5552400A (en) * 1994-06-08 1996-09-03 Sterling Winthrop Inc. Fused-bicyclic lactams as interleukin-1β converting enzyme inhibitors
US6420522B1 (en) * 1995-06-05 2002-07-16 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β converting enzyme
US5716929A (en) 1994-06-17 1998-02-10 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
US5756466A (en) * 1994-06-17 1998-05-26 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
US5856116A (en) * 1994-06-17 1999-01-05 Vertex Pharmaceuticals, Incorporated Crystal structure and mutants of interleukin-1 beta converting enzyme
US5847135A (en) * 1994-06-17 1998-12-08 Vertex Pharmaceuticals, Incorporated Inhibitors of interleukin-1β converting enzyme
US5565430A (en) * 1994-08-02 1996-10-15 Sterling Winthrop Inc. Azaaspartic acid analogs as interleukin-1β converting enzyme inhibitors
US5834514A (en) * 1995-05-30 1998-11-10 Vertex Pharmaceuticals, Incorporated Halomethyl amides as IL-1β protease inhibitors
US5744451A (en) 1995-09-12 1998-04-28 Warner-Lambert Company N-substituted glutamic acid derivatives with interleukin-1 β converting enzyme inhibitory activity
US5843904A (en) * 1995-12-20 1998-12-01 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1βconverting enzyme
US6096728A (en) * 1996-02-09 2000-08-01 Amgen Inc. Composition and method for treating inflammatory diseases
US6610683B2 (en) 1996-09-12 2003-08-26 Idun Pharmaceuticals, Inc. Treatment of infectious disease using interleukin-1β-converting enzyme (ICE)/CED-3 family inhibitors
US6200969B1 (en) 1996-09-12 2001-03-13 Idun Pharmaceuticals, Inc. Inhibition of apoptosis using interleukin-1β-converting enzyme (ICE)/CED-3 family inhibitors
US6531467B2 (en) 1996-09-12 2003-03-11 Idun Pharmaceuticals, Inc. Inhibition of inflammation using interleukin-1β-converting enzyme (ICE)/CED-3 family inhibitors
CA2265853C (en) 1996-09-12 2010-08-03 Idun Pharmaceuticals, Inc. Inhibition of apoptosis using interleukin-1.beta.-converting enzyme (ice)/ced-3 family inhibitors
JP2001508404A (ja) 1996-10-11 2001-06-26 ワーナー―ランバート・コンパニー スルホンアミドインターロイキン―１β変換酵素阻害剤
US5919790A (en) 1996-10-11 1999-07-06 Warner-Lambert Company Hydroxamate inhibitors of interleukin-1β converting enzyme
WO1998016504A2 (en) 1996-10-11 1998-04-23 Warner-Lambert Company SULFONAMIDE SUBSTITUTED ASPARTIC ACID INTERLEUKIN-1β CONVERTING ENZYME INHIBITORS
WO1998016502A1 (en) 1996-10-11 1998-04-23 Warner-Lambert Company ASPARTATE ESTER INHIBITORS OF INTERLEUKIN-1β CONVERTING ENZYME
ATE346085T1 (de) * 1996-12-06 2006-12-15 Vertex Pharma Inhibitoren des interleukin-1-beta konvertierenden enzyms
ATE290545T1 (de) * 1996-12-06 2005-03-15 Vertex Pharma Inhibitoren des interleukin-1beta konvertierenden enzyms
US6184244B1 (en) 1996-12-16 2001-02-06 Idun Pharmaceuticals, Inc. C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
JP2002509153A (ja) 1998-01-20 2002-03-26 ワーナー−ランバート・カンパニー インターロイキン−１β変換酵素（ＩＣＥ）のインビボ阻害剤としてのＮ−［２−（５−ベンジルオキシカルボニル−アミノ−６−オキソ−２−（４−フルオロフェニル）−１，６−ジヒドロ−１−ピリミジニル）アセトキシル］−Ｌ−アスパラギン酸アルデヒド
ES2244178T3 (es) * 1998-03-09 2005-12-01 Vertex Pharmaceuticals Incorporated Derivados de 1,2-diazepan como inhibidores de la enzima convertidora de interleuquina-1 beta.
KR20010041905A (ko) 1998-03-16 2001-05-25 시토비아 인크. 디펩티드 카스파제 억제제 및 이의 용도
IL139416A0 (en) 1998-05-05 2001-11-25 Warner Lambert Company Basf Ag Succinamide inhibitors of interleukin-1? converting enzyme
DE69937638T2 (de) * 1998-06-02 2008-10-30 Vertex Pharmaceuticals Inc., Cambridge Caspase-9 defiziente tiere und deren verwendung
EP1165490B1 (en) 1999-03-16 2006-08-16 Cytovia, Inc. Substituted 2-aminobenzamide caspase inhibitors and the use thereof
ATE363465T1 (de) 1999-04-09 2007-06-15 Cytovia Inc Caspase inhibitoren und ihre verwendung
DE60010675T2 (de) * 1999-08-06 2005-06-16 Vertex Pharmaceuticals Inc., Cambridge Caspase inhibitoren und deren verwendung
EA200200301A1 (ru) 1999-08-27 2002-08-29 Сайтовиэ, Инк. ЗАМЕЩЕННЫЕ α-ГИДРОКСИКИСЛОТЫ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СПОСОБ ИНГИБИРОВАНИЯ КЛЕТОЧНОЙ ГИБЕЛИ НА КЛЕТОЧНОМ ИЛИ ТКАНЕВОМ УРОВНЕ, СПОСОБ ЛЕЧЕНИЯ ИЛИ ОБЛЕГЧЕНИЯ СОСТОЯНИЯ ПРИ ГИБЕЛИ КЛЕТОК У ЖИВОТНОГО, СПОСОБ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ РАЗЛИЧНЫХ БОЛЕЗНЕЙ
US6566338B1 (en) 1999-10-12 2003-05-20 Cytovia, Inc. Caspase inhibitors for the treatment and prevention of chemotherapy and radiation therapy induced cell death
CA2389569A1 (en) * 1999-11-16 2001-05-25 Vertex Pharmaceuticals Incorporated Crystallizable compositions comprising a caspase-7
AR026748A1 (es) * 1999-12-08 2003-02-26 Vertex Pharma Un compuesto inhibidor de caspasas, una composicion farmaceutica que lo comprende, un metodo para la sintesis del mismo y un compuesto intermediario paradicha sintesis
MXPA02009633A (es) * 2000-03-29 2003-03-10 Vertex Pharma Inhibidores de carbamato caspasa y usos de los mismos.
AU2001253692B2 (en) * 2000-04-24 2006-11-02 Vertex Pharmaceuticals Incorporated Process and intermediates for making substituted aspartic acid acetals
RU2002135314A (ru) * 2000-05-04 2004-05-27 Вертекс Фармасьютикалз Инкорпорейтед (Us) Асимметричный синтез пиперазиновой кислоты и ее производных
WO2001094351A1 (en) * 2000-06-07 2001-12-13 Vertex Pharmaceuticals Incorporated Caspase inhibitors and uses thereof
CA2315468A1 (en) 2000-08-10 2002-02-10 Thermax International Corp. Multi grouting system
WO2002022611A2 (en) 2000-09-13 2002-03-21 Vertex Pharmaceuticals Incorporated Caspase inhibitors and uses thereof
WO2002042278A2 (en) * 2000-11-21 2002-05-30 Vertex Pharmaceuticals Incorporated Imidazole and benzimidazole caspase inhibitors and uses thereof
MXPA03009647A (es) * 2001-04-19 2004-01-29 Vertex Pharma Heterociclildicarbamidas como inhibidores de caspasa.
CA2445923A1 (en) 2001-05-10 2002-11-14 Abbott Gmbh & Co. Kg Arylsulfonamide ethers, and methods of use thereof
WO2002094263A2 (en) * 2001-05-23 2002-11-28 Vertex Pharmaceuticals Incorporated Caspase inhibitors and uses thereof
WO2003042169A2 (en) * 2001-10-09 2003-05-22 Vertex Pharmaceuticals Incorporated Process for synthesizing aspartic and glutamic acid derivatives and diazoketone intermediates thereof
WO2003072528A2 (en) 2002-02-08 2003-09-04 Idun Pharmaceuticals, Inc. (substituted)acyl dipeptidyl inhibitors of the ice/ced-3 family of cysteine proteases
WO2003068242A1 (en) * 2002-02-11 2003-08-21 Vertex Pharmaceuticals Incorporated Phospholipids as caspase inhibitor prodrugs
WO2004002401A2 (en) 2002-04-05 2004-01-08 Cytovia, Inc. Caspase inhibitors for the treatment of diseases and conditions caused by exposure to radionuclides, biological agents, or chemical agents
US7960398B2 (en) * 2002-04-19 2011-06-14 Vertex Pharmaceuticals Incorporated Regulation of TNF-alpha
US7138395B2 (en) 2002-06-10 2006-11-21 The Procter & Gamble Company Interleukin-1β converting enzyme inhibitors
US7001899B2 (en) 2002-06-10 2006-02-21 The Procter & Gamble Company Interleukin converting enzyme inhibitors
US7041696B2 (en) 2002-06-17 2006-05-09 The Procter & Gamble Company Interleukin-1β converting enzyme inhibitors
US7553852B2 (en) 2002-06-28 2009-06-30 Vertex Pharmaceuticals Incorporated Caspase inhibitors and uses thereof
AU2003303345A1 (en) 2002-12-20 2004-07-22 Vertex Pharmaceuticals, Inc. 4-oxo-3-(1-oxo-1h-isoquinolin-2-ylacetylamino)-pentanoic acid ester and amide derivatives and their use as caspase inhibitors
PE20050159A1 (es) * 2003-05-27 2005-04-19 Vertex Pharma Derivados de acido 3-[2-(3-amino-2-oxo-2h-piridin-1-il)-acetilamino]-4-oxo-pentanoico como inhibidores de caspasa
AU2004253967B2 (en) 2003-07-03 2010-02-18 Cytovia, Inc. 4-arylamino-quinazolines as activators of caspases and inducers of apoptosis
WO2005047906A1 (en) * 2003-11-10 2005-05-26 Vertex Pharmaceuticals Incorporated Methods for monitoring il-18
US20050233974A1 (en) * 2003-12-01 2005-10-20 John Randle Treating infectious diseases using ice inhibitors
AR047981A1 (es) * 2004-02-27 2006-03-15 Vertex Pharma Inhibidores de caspasa y sus usos correspondientes
DK2399915T3 (en) * 2004-03-12 2015-03-09 Vertex Pharma A process and intermediates for the preparation of asparaginacetal-caspase inhibitors
US7531570B2 (en) * 2004-05-27 2009-05-12 Vertex Pharmaceuticals Incorporated Treatment of diseases using ICE inhibitors
JP5055129B2 (ja) * 2004-11-24 2012-10-24 バーテックス ファーマシューティカルズ インコーポレイテッド ３−［２−（３−アシルアミノ−２−オキソ−２ｈ−ピリジン−１−イル）−アセチルアミノ］−４−オキソ−ペンタン酸誘導体、およびカスパーゼ阻害剤としてのそれらの使用
KR20080038369A (ko) * 2005-07-28 2008-05-06 버텍스 파마슈티칼스 인코포레이티드 카스파제 억제제 프로드럭

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1229412A (zh) * 1995-12-20 1999-09-22 沃泰克斯药物股份有限公司 白细胞介素－1β转化酶抑制剂
US6531474B1 (en) * 1998-03-19 2003-03-11 Vertex Pharmaceuticals Incorporated Inhibitors of caspases
US20020013278A1 (en) * 2000-05-19 2002-01-31 Wannamaker Marion W. Prodrug of an ice inhibitor
WO2001090070A2 (en) * 2000-05-23 2001-11-29 Vertex Pharmaceuticals Incorporated Caspase inhibitors and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
向赟 等: "海马白细胞介素－1β与癫痫研究进展", 《江汉大学学报（自然科学版）》 *
曹海燕 等: "白细胞介素1与惊厥性脑损伤", 《生理科学进展》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105392775A (zh) * 2013-07-18 2016-03-09 辛泰格有限公司 旋光异构体：(+)-二苯甲基脲和(-)-二苯甲基脲以及(+)-1-[（3-氯苯基)-苯基-甲基]脲和(-)-1-[（3-氯苯基)-苯基-甲基]脲，它们的药物制剂及其制备方法

Also Published As

Publication number Publication date
WO2005115362A1 (en) 2005-12-08
AU2005247409B2 (en) 2011-11-10
IL179248A0 (en) 2008-04-13
NZ588448A (en) 2012-01-12
CA2566362A1 (en) 2005-12-08
ZA200610133B (en) 2008-05-28
PL381823A1 (pl) 2007-07-23
MXPA06013256A (es) 2007-02-08
CN1980648A (zh) 2007-06-13
CA2566362C (en) 2013-09-10
JP2007538013A (ja) 2007-12-27
EP1750689A1 (en) 2007-02-14
US20060128696A1 (en) 2006-06-15
JP2011213741A (ja) 2011-10-27
JP4848367B2 (ja) 2011-12-28
US20150190404A1 (en) 2015-07-09
AU2005247409A1 (en) 2005-12-08
PL217743B1 (pl) 2014-08-29

Similar Documents

Publication Publication Date Title
JP7752220B2 (ja) 前立腺癌の治療方法
US20150190404A1 (en) Treating seizures using ice inhibitors
TWI222360B (en) Treating or preventing the early stages of degeneration of articular cartilage or subchondral bone in mammals using carprofen and derivatives
AU2016396658B2 (en) Treatment of autoimmune diseases with combinations of RXR agonists and thyroid hormones
JP2023113715A (ja) 子宮内膜症の治療のためのゴナドトロピン放出ホルモンアンタゴニスト投与計画
Altan et al. A long-acting tumor necrosis factor α-binding protein demonstrates activity in both in vitro and in vivo models of endometriosis
WO2005034937A1 (en) Composition for treatment of osteoarthritis containing apigenin as chindroregenerative agent
EP1347751B1 (en) Methods of treating bone cancer and the pain associated therewith using endothelin antagonists
JP2007538013A5 (enExample)
EP3873465B1 (en) Compositions and methods for the treatment of adenomyosis and rectovaginal endometriosis
RU2423692C2 (ru) Вещества для профилактики и лечения панкреатита
KR101190529B1 (ko) Ｉｃｅ 억제제를 사용하는 발작의 치료
HK1166613A (en) Treating seizures using ice inhibitors
HK1103922A (en) Treating seizures using ice inhibitors
JP2024020797A (ja) 筋萎縮の治療剤
JP2000080032A (ja) 排出障害治療剤
HK40059353B (en) Compositions and methods for the treatment of adenomyosis and rectovaginal endometriosis
HK40059353A (en) Compositions and methods for the treatment of adenomyosis and rectovaginal endometriosis
Coelho Small Animal Medicine and Surgery
EA049291B1 (ru) Способы лечения рака предстательной железы
Wu et al. Glutamatergic neural pathways in the nucleus tractus solitarius play A critical role in mediating pancreatic secretion evoked by non-CCK-dependent luminal factors
KR20030007314A (ko) 카르프로펜 및 그의 유도체를 포함하는, 포유류에서 관절연골 또는 연골하 골의 초기 단계의 퇴행을 치료 또는예방하기 위한 약학적 조성물 및 팩키지
Altan et al. A Long Acting TNFα Binding Protein Demonstrates Activity in both in vitro and in vivo Models of Endometriosis

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1166613

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20120229

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1166613

Country of ref document: HK